These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 1588151

  • 1. Preparation, antigenicity, and immunogenicity of synthetic ribosylribitol phosphate oligomer-protein conjugates and their potential use for vaccination against Haemophilus influenzae type b disease.
    Evenberg D, Hoogerhout P, van Boeckel CA, Rijkers GT, Beuvery EC, van Boom JH, Poolman JT.
    J Infect Dis; 1992 Jun; 165 Suppl 1():S152-5. PubMed ID: 1588151
    [Abstract] [Full Text] [Related]

  • 2. Immune response of young children vaccinated with Haemophilus influenzae type b conjugate vaccines.
    Madore DV, Phipps DC, Eby R, Johnson CL, Smith DH.
    Contrib Microbiol Immunol; 1989 Jun; 10():125-50. PubMed ID: 2684505
    [No Abstract] [Full Text] [Related]

  • 3. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid.
    Decker MD, Edwards KM, Bradley R, Palmer P.
    J Pediatr; 1993 Mar; 122(3):410-3. PubMed ID: 8441096
    [Abstract] [Full Text] [Related]

  • 4. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y, Granoff DM.
    JAMA; 1992 Mar 18; 267(11):1489-94. PubMed ID: 1538539
    [Abstract] [Full Text] [Related]

  • 5. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B, Wald E, Guerra N, Byers C.
    Pediatrics; 1990 Apr 18; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [Abstract] [Full Text] [Related]

  • 6. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines.
    Käyhty H, Eskola J, Peltola H, Saarinen L, Mäkelä PH.
    J Infect Dis; 1992 Jun 18; 165 Suppl 1():S165-6. PubMed ID: 1588156
    [No Abstract] [Full Text] [Related]

  • 7. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.
    Kaplan SL, Duckett T, Mahoney DH, Kennedy LL, Dukes CM, Schaffer DM, Mason EO.
    J Pediatr; 1992 Mar 18; 120(3):367-70. PubMed ID: 1538281
    [Abstract] [Full Text] [Related]

  • 8. Haemophilus influenzae type B conjugate vaccines.
    Kaplan SL.
    Pediatr Ann; 1990 Dec 18; 19(12):712-3, 716-8. PubMed ID: 2280990
    [No Abstract] [Full Text] [Related]

  • 9. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide and its tetanus toxoid conjugate in patients with recurrent infections or humoral immunodeficiency.
    Barra A, Bremard-Oury C, Bajart A, Griscelli C, Fritzell B, Preud'homme JL.
    Int J Clin Lab Res; 1992 Dec 18; 21(3):231-4. PubMed ID: 1591374
    [Abstract] [Full Text] [Related]

  • 10. Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers.
    Anderson PW, Stein EC, Insel RA.
    Contrib Microbiol Immunol; 1989 Dec 18; 10():115-24. PubMed ID: 2684504
    [No Abstract] [Full Text] [Related]

  • 11. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).
    Vella PP, Staub JM, Armstrong J, Dolan KT, Rusk CM, Szymanski S, Greer WE, Marburg S, Kniskern PJ, Schofield TL.
    Pediatrics; 1990 Apr 18; 85(4 Pt 2):668-75. PubMed ID: 2107517
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Finnish efficacy trials with Haemophilus influenzae type b vaccines.
    Eskola J, Peltola H, Käyhty H, Takala AK, Mäkelä PH.
    J Infect Dis; 1992 Jun 18; 165 Suppl 1():S137-8. PubMed ID: 1588148
    [Abstract] [Full Text] [Related]

  • 16. Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys.
    Peeters CC, Evenberg D, Hoogerhout P, Käyhty H, Saarinen L, van Boeckel CA, van der Marel GA, van Boom JH, Poolman JT.
    Infect Immun; 1992 May 18; 60(5):1826-33. PubMed ID: 1563770
    [Abstract] [Full Text] [Related]

  • 17. Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid.
    Bergquist C, Lagergård T, Holmgren J.
    APMIS; 1998 Aug 18; 106(8):800-6. PubMed ID: 9744766
    [Abstract] [Full Text] [Related]

  • 18. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM, Holmes SJ, Belshe RB, Osterholm MT, McHugh JE, Anderson EL.
    JAMA; 1994 Oct 12; 272(14):1116-21. PubMed ID: 7933324
    [Abstract] [Full Text] [Related]

  • 19. Biological activity of Hib conjugates.
    Vella PP, Staub JM, Ellis RW.
    Vaccine; 1991 Jun 12; 9 Suppl():S26-9; discussion S42-3. PubMed ID: 1891953
    [Abstract] [Full Text] [Related]

  • 20. Physicochemical studies of the structure and stability of polysaccharide-protein conjugate vaccines.
    Jones C, Crane DT, Lemercinier X, Bolgiano B, Yost SE.
    Dev Biol Stand; 1996 Jun 12; 87():143-51. PubMed ID: 8854011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.